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Abstract Hepatocytes are the source of plasma fibronectin
(FN) which lacks the alternatively spliced EDI segment,
distinctive of oncofetal FN. When hepatic or other epithelial
cells are cultured on plastic, EDI inclusion is triggered. Here we
report that EDI inclusion is inhibited when hepatic cells are
cultured on a basement membrane-like extracellular matrix
(ECM), demonstrating a new role for the ECM in the control of
gene expression. The effect is duplicated by collagen IV and
laminin but not by collagen I; is not observed with another
alternatively spliced FN exon (EDII); and correlates with a
decrease in cell proliferation, consistently with high EDI
inclusion levels observed in many physiological and pathological
proliferative processes. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
It is now estimated that more than 50% of human genes
generate diversity through alternative mRNA splicing [1,2].
This process can be regulated in a cell type-, development-,
and age-dependent manner. In the case of the human ¢bro-
nectin (FN) gene, alternative splicing in three di¡erent regions
referred to as EDII, EDI and IIICS gives rise to up to 20
di¡erent mRNAs and polypeptides in a cell-speci¢c manner.
In vivo, EDI+ FN is poorly represented in the extracellular
matrix (ECM) of adult normal tissues. However, this variant
is overexpressed in developing embryos [3], wound healing [4],
liver ¢brosis [5], ovary granulosa cell proliferation [6] and
some tumors [7].
Although the roles of cis and trans-acting elements in the
control of alternative splicing has been emerging [8,9], little is
known about the extracellular signals and transduction path-
ways that control this event. Changes in alternative splicing of
several pre-mRNAs upon stimulation by growth factors, cy-
tokines, hormones and stress stimuli have been reported [10-
12].
Cell-ECM interactions initiate a dynamic £ow of informa-
tion that acts to regulate many fundamental processes
throughout development. These include cell migration in the
early embryo, morphogenesis during organ formation, and the
modulation of growth, survival and di¡erentiation of many
specialized cell types [13,14]. Mechanical and biochemical con-
nections between the ECM and the cell nucleus lead to
changes in gene expression [15,16].
In the present study we report that a laminin-rich basement
membrane as well as its two main protein components, lam-
inin and type IV collagen, are able to modulate the alternative
splicing of the FN EDI exon. This e¡ect is independent from
the promoter and does not in£uence another FN alternative
exon, EDII.
2. Materials and methods
2.1. Cell culture
The human hepatoma cell line Hep3B was routinely grown in Dul-
becco’s modi¢ed Eagle’s medium (DMEM; Gibco BRL) containing
10% (v/v) heat-inactivated fetal bovine serum (FBS), and penicillin/
streptomycin (100 units/ml and 100 Wg/ml respectively; Gibco BRL).
2.2. Transfections
Stable or transient transfections were performed using Lipofectam-
ine reagent (Gibco/BRL) according to the manufacturer’s instructions.
For transient transfection assays, approximately 1.5U105 cells were
transfected with 2 Wg of plasmid DNA and 6 Wl of lipofectamine in 35
mm-tissue culture dishes. After 6 h, the transfection mixture was
replaced by fresh DMEM, 0.25% (v/v) FBS, with or without Matrigel
treatment (see cell treatments). Co-transfection with the pCMV-L-ga-
lactosidase plasmid allowed standardization of the RNA samples by
transfection e⁄ciencies: an aliquot of the cells was used to measure L-
galactosidase activity and the rest was used to prepare total RNA.
Stable cell lines used here were reported previoulsy [17].
2.3. Cell treatments
Approximately 1.5U104 cells/cm2 were plated in DMEM supple-
mented with 1% (v/v) FBS. After 24 h, the medium was replaced with
0.25% (v/v) FBS-DMEM with or without the correspondent treat-
ment: 1.5% (v/v) Matrigel, Type I or IV collagens, human plasma
¢bronectin (Collaborative Biomedical Products), laminin (Sigma),
BSA (Promega), TGF L1 (2,5 ng/ml) (provided by Tomas Santa
Coloma), EGF (50 ng/ml), HGF-SF (25 ng/ml) (Collaborative Bio-
medical Products). The cells were maintained for 72 h except when
indicated, with a change of medium plus treatment after 48 h. Experi-
ments were always run in duplicates.
2.4. RNA isolation and radioactive RT-PCR ampli¢cation
Total RNA puri¢cation from cultured cells and RT-PCR analysis
was carried out as previously described [18].
The sets of primers used were:
pSV5Pj and pSV3Pj for the ampli¢cation of the minigene splicing
products [19].
hFN-dir4860 (5P AGCCCCGCAAGCAGCAAGCC 3P) and hFN-
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rev5758 (5P GTAGCATCTGTCACACGAG 3P) for endogenous FN
mRNAs containing or lacking the EDI exon.
hEDB-dir (5P GCATCTGGAGGCAAACCCTGAC 3P) and
hEDB-rev (5P GTCAATGCCAGTTGGGGAATCAAG 3P) for en-
dogenous FN mRNAs containing or lacking the EDII exon.
RT-PCR products were electrophoresed in 6% (w/v) polyacrylamide
native gels and detected by autoradiography. Radioactivity in the
bands was measured in a scintillation counter (Cerenkov method).
2.5. Cell proliferation assay
DNA synthesis was measured by [3H]-thymidine incorporation.
Cells were cultured with or without Matrigel during 3 days. Either
18 or 6 h prior to the ending of the 3 day-period, 1 Wl of [3H]-thymi-
dine (1 mCi/ml) was added to each well of 24-well plates.
After the corresponding incubation time, cells were washed twice
with cold PBS, incubated at 4‡C with cold 5% trichloro acetic acid
(TCA) during 50 min, washed once with cold PBS, and incubated
O/N at room temp. with 0.5 M NaOH/0.1% (v/v) triton X-100.
Cell lysates were mixed with scintillation £uid and counted in a scin-
tillation counter.
2.6. Substrata
When indicated, 35 mm-tissue culture wells were pre-coated on ice
with 0.2 ml of cold Matrigel. Matrigel was then allowed to gel at
37‡C during 15 min and cells were immediately plated on top of it.
For studies on the in£uence of cell shape, culture plates were coated
with the non-adhesive substratum poly(2-hydroxyethyl methacryl-
ate) (‘polyHEMA’; Sigma) as described [20,21], at concentration of
3 mg/ml in 95% ethanol before drying.
3. Results
3.1. Basement membrane-like ECM inhibits FN EDI exon
inclusion
To study the in£uence of the cellular microenvironment on
FN alternative splicing we evaluated the e¡ect of an exoge-
nous extracellular matrix on FN EDI exon inclusion. Hep3B
cells were cultured with or without an overlay of a laminin-
rich basement membrane (Matrigel). Cells were harvested
after di¡erent time points, total RNA was puri¢ed and sub-
jected to RT-PCR with primers designed to assess EDI inclu-
sion levels (Fig. 1A). The addition of Matrigel inhibited the
inclusion of the EDI exon by 40^50% as shown in Fig. 1B.
This e¡ect was clearly detected after 3 days of treatment and
persisted for at least 5 days.
As an alternative approach, Matrigel was used as a sub-
stratum and Hep 3B cells were either plated directly on tissue
culture plastic or on top of a thick basement membrane gel.
Despite the fact that these two ways of treatment with Ma-
trigel induced di¡erent degrees of cell shape changes (Fig. 1C),
they elicited similar results with respect to the regulation of
EDI alternative splicing.
The basement membrane e¡ect on alternative splicing was
almost abolished when cells were cultured with 10% (v/v) se-
rum but became more and more pronounced with decreasing
concentrations of serum. As Hep3B cells do not survive long
periods under serum deprivation, we reduced the level of se-
rum to 0.25%, condition that kept the cells healthy for more
than 72 h and allowed us to observe a signi¢cant inhibition of
EDI inclusion when Matrigel was added.
We then decided to evaluate whether the basement mem-
brane could regulate another FN alternative exon, EDII (also
known as EDB or EIIIB). PCR reactions with the same
cDNAs already tested for EDI inclusion but with a di¡erent
pair of primers, speci¢c for EDII splicing (Fig. 1A), revealed
that the splicing pattern of the EDII exon was not modi¢ed
upon addition of Matrigel (Fig. 2).
3.2. Inhibition of EDI inclusion by basement membrane does
not depend on either promoter or chromatin structures
Our laboratory has demonstrated that di¡erences in pro-
moter structure control splice site selection [22], providing
evidence for coupling between alternative splicing and tran-
scription machineries. Based on these results we decided to
investigate whether the observed basement membrane-induced
inhibition of EDI inclusion was dependent on promoter ar-
chitecture. We used a formerly reported system, consisting in
the transfection of Hep3B cells with K-globin/¢bronectin min-
igenes under the control of di¡erent promoters (FN, cytomeg-
alovirus and K-globin) [22] (Fig. 3A). Total RNA from trans-
fected cells was extracted and subjected to RT-PCR with 2
di¡erent pairs of primers. One set of primers to analyze the
mRNA isoforms generated from the endogenous FN gene
(Fig. 1A) and another set to analyze the isoforms generated
from the minigene (Fig. 3A). In every case, the Matrigel in-
hibited EDI inclusion independently from the promoter that
gave rise to the transcripts. Moreover, the e¡ect was observed
whether the minigene was transfected transiently or stably
into the cells, suggesting that this splicing regulation does
not depend on chromatin organization. Nevertheless, the ef-
fect was more pronounced (up to 60% inhibition of EDI exon
inclusion) with one of the minigenes analyzed, pFNmut, sta-
bly transfected into Hep3B cells (Fig. 3B). For that reason we
continued our studies with this cell clone, named ‘Hep3B FN
mut1’. In every experiment we evaluated EDI exon inclusion
in transcripts derived from both the endogenous FN gene as
well as the inserted minigene, obtaining similar results.
3.3. Regulation of EDI inclusion by basement membrane
proteins
To assure that the changes observed were not due to con-
taminating growth factors present in the Matrigel prepara-
tion, we tested the e¡ect of a Matrigel partially depleted of
growth factors (GFR Matrigel) as well as di¡erent available
growth factors (TGF L1; EGF; HGF/SF) on FN EDI alter-
native splicing in Hep3B FN mut1 cells.
GFR Matrigel was able to inhibit the inclusion of EDI exon
to the same extent as regular Matrigel (Fig. 3B). In addition,
the three growth factors tested showed the opposite e¡ect,
that means they induced the inclusion of this exon (Fig.
3C). These results are in agreement with previous reports in
other cell systems that showed that TGF L1 as well as HGF/
SF stimulates EDI inclusion [23^26]. None of the tested
growth factors was able to alter the pattern of EDII exon
inclusion (data not shown).
Matrigel main components are laminin (60%) and type IV
collagen (30%). To determine whether any of these two pro-
teins is able to trigger the inhibition of FN EDI inclusion,
Hep3B FN mut1 cells were cultured either with puri¢ed lam-
inin or type IV collagen during 3 days. We also tested the
e¡ect of type I collagen and ¢bronectin, two additional
ECM proteins that are not usually associated with the base-
ment membrane, and also of bovine serum albumin. We
treated Hep3B FN mut1 cells with 150 Wg/ml of these puri¢ed
proteins, a dose equivalent to the amount of laminin present
in the volume of Matrigel previously used. Under these con-
ditions, both laminin and type IV collagen inhibited EDI exon
inclusion similarly to Matrigel (Fig. 4A). Neither type I col-
lagen nor bovine serum albumin elicited any e¡ect on EDI
alternative splicing (Fig. 4B). Treatment with plasma FN re-
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Fig. 1. E¡ect of a reconstituted basement membrane (Matrigel) on
EDI alternative splicing. A. Fragment of the endogenous FN gene
showing EDI (black box) and EDII (dashed box) alternative exons
with their neighboring introns (lines) and exons (white boxes). Ar-
rows indicate positions of the primers used for ampli¢cation of FN
EDI+ and EDI3 or FN EDII+ and EDII3 mRNA isoforms. B.
RT-PCR analysis of endogenous FN EDI+ and EDI3 mRNA iso-
forms produced by Hep3B cells cultured in the absence (3) or pres-
ence (+) of a Matrigel overlay. Quanti¢cation of each band was car-
ried out with a scintillation counter. EDI+/EDI3 ratios shown in
the histogram are the average of three independent experiments. C.
Morphology of Hep3B cells cultured for three days in the absence
of Matrigel (a), with a Matrigel overlay (b) or on top of a Matrigel
gel (c). Magni¢cation: 100U.
Fig. 2. E¡ect of Matrigel on EDII alternative splicing. RT-PCR
analysis of endogenous FN EDII+ and EDII3 mRNA isoforms
produced by Hep3B cells cultured in the absence (3) or presence
(+) of a Matrigel overlay. Quanti¢cation of each band was carried
out with a scintillation counter. EDII+/EDII3 ratios shown in the
histogram are the average of three independent experiments.
Fig. 3. E¡ect of Matrigel and growth factors on EDI alternative
splicing in Hep3B FN mut1 cells. A. Scheme of the minigene stably
transfected into Hep3B cells. The cartoon shows a promoter (dashed
box) driving the expression of the minigene composed by K-globin
exons (with boxes), K-globin introns (dotted lines), FN introns
(black lines) and FN exons (gray and black boxes). EDI exon is
shown in black. Arrows indicate positions of the primers used for
ampli¢cation of FN EDI+ and EDI3 mRNA isoforms generated
from the transgene. B-C. RT-PCR analysis of EDI+ and EDI3
mRNA isoforms derived from a stably transfected minigene (pFN
mut) in Hep3B cells. B. Cells were cultured in the absence (3) or
presence of regular Matrigel (Matrigel) or growth factor reduced
(GFR)-Matrigel (GFR-M). C. Cells were cultured without the addi-
tion of any growth factor (3) or with EGF, HGF-SF or TGFL1.
EDI+/EDI3 ratios shown in the histograms are the average of
three independent experiments.
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sulted in cell detachment, making hardly impossible to draw
any conclusion on the e¡ect of this protein on FN alternative
splicing in this cell type.
3.4. EDI exclusion vs. proliferation
Overexpression of EDI+ FN is associated with several pro-
liferative processes [7]. On the other hand, it has been shown
that many cell types undergo growth arrest when cultured
with a basement membrane [27,28]. Therefore, we asked
whether the observed inhibition of EDI inclusion in Hep3B
cells could correlate with an inhibition in cell-cycle progres-
sion. To answer this question, Hep3B FN mut 1 cells were
cultured for 3 days with or without Matrigel and with 0.25%
(v/v) serum and during the last 18 or 6 h of the experiment the
percentage of cells entering the S-phase was measure by [3H]-
thymidine incorporation. Fig. 5 shows a signi¢cant decrease in
the fraction of cells entering S-phase when cultured in the
presence of Matrigel compared to cells cultured in its absence.
4. Discussion
We show here that Matrigel, a basement membrane-like
ECM, can regulate pre-mRNA splicing. As ECMs are com-
plex three-dimensional arrays of several proteins and can also
contain multiple bound growth factors, we dissected the com-
position of Matrigel into its main components and found that
laminin and type IV collagen are able to down regulate the
inclusion of the FN EDI alternative exon into mature mRNA.
Our ¢ndings agree with reports that di¡erent collagen species
are able to alter promoter usage and mRNA splicing patterns
of parathyroid hormone-related peptide (PTHrP) in a human
breast cancer cell line [29].
It is known that regular, two-dimensional tissue culture
conditions represent quite an abnormal microenvironment,
not permissive for sustained tissue-speci¢c functions [30,31].
In agreement with this concept, our ¢nding that Hep3B cells
in contact with a basement membrane not only downregulate
the expression of the EDI+ FN isoform but also show a
dramatic decrease in cell cycle progression correlates well
with the already described expression pattern of EDI+ FN
in vivo. On one hand, plasma FN, which lacks EDI, is
made by hepatocytes which are lying on their basement mem-
branes in vivo [32]. Culture of these cells on plastic triggers
FN EDI inclusion. On the other hand, inclusion of EDI exon
is greatly increased in physiological and pathological process-
es that involve cell proliferation, such as embryo development
[3], wound healing [4], vascular intima thickening [33], regen-
erating liver [34] and ovarian follicular development [6].
When cells are placed on a reconstituted basement mem-
brane not only signalling pathways are activated by integrin
ligands but also dramatic changes in cell morphology take
place [21]. Schischmano¡ et al. [35] showed previously that
the alternative splicing of the pre-mRNA for protein 4.1 is
modulated by changes in cell shape in mammary epithelial
cells. Hep3B FN mut1 cells can be forced to change their
shape without the addition of Matrigel, by plating them
onto an inert, non-adhesive polymer, poly(2-hydroxyethyl
methacrylate) (poly-HEMA) [20]. Under these conditions,
the cells aggregate in rounded clusters that remain in suspen-
sion. Hep3B FNmut1 cells plated on polyHEMA-coated
dishes also displayed downregulation of EDI exon inclusion
(not shown). This e¡ect was smaller than the one exerted by
the Matrigel, suggesting that the cell shape change is indeed
involved in the regulation but it is not su⁄cient to produce
the whole e¡ect. However, we can not rule out the possibility
that the change in cell shape induces the deposition of some
endogenous basement membrane [28,36], which in turn leads
to the downregulation of EDI exon inclusion.
The inhibitory e¡ect of Matrigel on EDI splicing correlates
Fig. 4. E¡ect of puri¢ed proteins on EDI alternative splicing in
Hep3B FN mut 1 cells. A. Cells were treated with Matrigel, lami-
nin, or type IV collagen (col IV) or left untreated (3). B. Cells were
treated with bovine serum albumin (BSA) or type I collagen (col I)
or left untreated (3). EDI+/EDI3 ratios corresponding to each
treatment shown in the histograms are expressed as the percentage
of the EDI+/EDI3 ratio from untreated cells.
Fig. 5. E¡ect of Matrigel on the rate of cell-cycle progression. Cell
proliferation assay of Hep3B FN mut 1 cells cultured in the absence
(3Matrigel) or presence (+Matrigel) of a Matrigel overlay. The in-
corporation of [3H]-thymidine was carried out during the last 6 or
last 18 h of the experiment.
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with a decrease in cell proliferation. The di¡erent steps in
mRNA processing are regulated by protein phosphorylation
and dephosphorylation of splicing factors such as SR pro-
teins.
It has been reported that the protein casein kinase IK is able
to phosphorylate SR proteins and at the same time plays a
role in cell cycle progression [37]. In this context, it is possible
to speculate that SR proteins involved in FN alternative splic-
ing are phosphorylated-dephosphorylated in a cell cycle-de-
pendent manner, therefore linking proliferation with EDI
exon inclusion. It has been shown that the EDI segment of
FN can act as a mitogen [6], therefore it would be possible to
postulate that the absence of basement membrane-dependent
signals leads to an increase in EDI+ FN synthesis and secre-
tion, which in turn triggers cellular proliferation in an auto-
crine or paracrine way.
Our results showing that FN EDII alternative splicing is
not modulated by Matrigel neither but few growth factors
that do regulate EDI are consistent with the idea that alter-
native splicing of EDI and EDII exons is controlled by di¡er-
ent molecular mechanisms [17,18,38].
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